PT - JOURNAL ARTICLE AU - Ng, Sweet Ping AU - Hall, Carolyn S AU - Meas, Salyna AU - Sarli, Vanessa N AU - Bahig, Houda AU - Cardenas, Carlos E AU - Elgohari, Baher AU - Wang, JiHong AU - Johnson, Jason M AU - Moreno, Amy C AU - Skinner, Heath AU - Garden, Adam S AU - Na, Lumine AU - Yuan, Ying AU - Urbauer, Diana AU - Phan, Jack AU - Gunn, G Brandon AU - Frank, Steven J AU - Shah, Shalin AU - Rosenthal, David I AU - Morrison, William H AU - MacManus, Michael P AU - Fuller, Clifton D AU - Lucci, Anthony TI - Circulating tumour cell and cell-free DNA kinetics during radiotherapy in patients with intact head and neck squamous cell carcinoma AID - 10.1101/2020.10.13.20211516 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.13.20211516 4099 - http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211516.short 4100 - http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211516.full AB - Head and neck squamous cell carcinoma (HNSCC) treatment response relies heavily on macroscopic clinical findings. Blood monitoring of circulating markers during treatment may improve earlier detection of responders versus non-responders during radiotherapy. In this study, patients with intact tumour of HNSCC were enrolled in the prospective PREDICT-HN study. Pre-, after first treatment, weekly, and post-treatment blood samples were collected. CTC was enumerated using the CellSearch system. cfDNA was quantified from cfNA isolated at pre-, mid- and post-treatment timepoints. Blood samples were collected from 45 patients. Of the 339 samples analysed for CTC, 31% had detectable CTCs. Nine patients had detectable CTCs (1-3/7.5ml blood) in pre-treatment samples. After 1 fraction, 16 patients had CTCs detected, with 12 who had no pre-treatment CTC. Sixteen (36%) patients had detectable CTC in final week of treatment. There was no correlation between cancer stage, nodal status and tumour burden with CTC. cfDNA levels increased during treatment, with its highest level in the final week and lowest at post-treatment. Our results showed in HNSCC that CTCs can be detected during radiotherapy, suggesting mobilization into circulation during treatment, with as-yet-unknown viability. cfDNA kinetics during treatment correlated with CTC release, and may indicate apoptotic change.Simple Summary Head and neck squamous cell carcinoma (HNSCC) treatment response relies heavily on macroscopic clinical findings. Blood monitoring of circulating markers such as circulating tumour cell (CTC) and cell-free DNA (cfDNA) during treatment may improve earlier detection of responders versus non-responders during definitive radiotherapy. Although the detection of CTCs and cfDNA in patients with HNSCC has been described, there is minimal data on the kinetics of CTC counts and cfDNA levels during radiotherapy in patients with HNSCC. Here, our study prospectively describes the changes in CTC and cfDNA enumeration during radiotherapy in patients with HNSCC. Our results showed, for the first time to our knowledge, in HNSCC, that CTCs can be detected during radiotherapy, suggesting mobilization into peripheral circulation during treatment, with as-yet-unknown viability. cfDNA kinetics during treatment correlated with CTC release, may indicate apoptotic change during radiotherapy. Combined cfDNA-CTC as an early marker of treatment response should be investigated further.Competing Interest StatementDr. Fuller has received grant support, speaker, and travel fees from Elekta AB.Clinical TrialNCT03491176Clinical Protocols https://doi.org/10.1007/978-1-0716-0759-6_9 Funding StatementDr. Ng is funded by the Australian Postgraduate Award, the Royal Australian and New Zealand College of Radiologists (RANZCR) Research Grant and the Radiological Society of North America (RSNA) Fellow Grant. This work was supported by Andrew Sabin Family Fellowship. Dr. Fuller receive funding support from the National Institutes of Health (NIH)/National Institute for Dental and Craniofacial Research (NIDCR) (1R01DE025248-01/R56DE025248-01). Dr. Fuller was previously funded via the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF DMS-1557679) and is currently supported by the NIH National Cancer Institute (NCI)/Big Data to Knowledge (BD2K) Program (1R01CA214825-01), the NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Research Program Career Development Award (P50CA097007-10); the NCI Paul Calabresi Clinical Oncology Program Award (K12 CA088084-06); a General Electric Healthcare/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award; an Elekta AB/MD Anderson Department of Radiation Oncology Seed Grant; the Center for Radiation Oncology Research (CROR) at MD Anderson Cancer Center Seed Grant; and the MD Anderson Institutional Research Grant (IRG) Program. Dr. Fuller has received speaker travel funding from Elekta AB. Supported in part by the NIH/NCI Cancer Center Support (Core) Grant CA016672 to The University of Texas MD Anderson Cancer Center (P30 CA016672).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB oversight provided by MD Anderson cancer Center under protocol PA_16_1041.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are embargoed pending peer-review and data descriptor publication; in the interim, data are available upon request at the discretion of PI(s) via contact email. A meta-data link for public data deposition is included for post-embargo data deposition. https://figshare.com/articles/dataset/_/13082309